Johnson & Johnson: Prostatic Neoplasms, Castration-Resistant trials

The registry lists 10 Prostatic Neoplasms, Castration-Resistant studies with Johnson & Johnson as lead sponsor. 3 are open to participants now and 2 have results posted.

Phase 1 5Phase 2 2Phase 3 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate CancerRecruitingNCT07225946Phase 3
• A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)RecruitingNCT07164443Phase 3
• A Rollover Study for Continued Study Treatment and Ongoing Safety MonitoringEnrolling by invitationNCT06788509Phase 1
• A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingNCT03748641Phase 3Results posted
• A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT03431350Phase 2Results posted
• A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT03551782Phase 1
• A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate CancerWithdrawnNCT02906605Phase 2
• Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate CancerCompletedNCT02625857Phase 1
• A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate CancerActive, not recruitingNCT02592317Phase 1
• A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1